C. B. Granger

6.0k total citations · 2 hit papers
42 papers, 4.2k citations indexed

About

C. B. Granger is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, C. B. Granger has authored 42 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Cardiology and Cardiovascular Medicine, 6 papers in Surgery and 5 papers in Internal Medicine. Recurrent topics in C. B. Granger's work include Heart Failure Treatment and Management (13 papers), Acute Myocardial Infarction Research (13 papers) and Atrial Fibrillation Management and Outcomes (9 papers). C. B. Granger is often cited by papers focused on Heart Failure Treatment and Management (13 papers), Acute Myocardial Infarction Research (13 papers) and Atrial Fibrillation Management and Outcomes (9 papers). C. B. Granger collaborates with scholars based in United States, Canada and United Kingdom. C. B. Granger's co-authors include Salim Yusuf, John J.V. McMurray, Jan Östergren, Eric L. Michelson, Karl Swedberg, Bertil Olofsson, Peter Held, Lars Wallentin, Jonas Oldgren and Agneta Siegbahn and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.

In The Last Decade

C. B. Granger

41 papers receiving 4.0k citations

Hit Papers

CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESART... 2003 2026 2010 2018 2003 2008 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL
    2003 794 citations John J.V. McMurray, Jan Östergren et al. The Lancet profile →
  2. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    2008 503 citations Michael R. MacDonald, Mark C. Petrie et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. B. Granger United States 24 3.6k 767 598 543 324 42 4.2k
Serafina Valente Italy 30 2.5k 0.7× 444 0.6× 1.3k 2.1× 407 0.7× 542 1.7× 162 3.7k
Anselm K. Gitt Germany 39 3.4k 0.9× 761 1.0× 1.7k 2.9× 287 0.5× 354 1.1× 173 4.8k
Erik Lerkevang Grove Denmark 38 3.3k 0.9× 342 0.4× 1.3k 2.2× 1.1k 1.9× 443 1.4× 251 5.1k
Jayashri Aragam United States 28 2.1k 0.6× 239 0.3× 356 0.6× 321 0.6× 362 1.1× 57 2.8k
Mikael Dellborg Sweden 27 2.3k 0.6× 359 0.5× 764 1.3× 346 0.6× 441 1.4× 126 3.2k
Young‐Hoon Jeong South Korea 31 2.6k 0.7× 328 0.4× 1.4k 2.3× 631 1.2× 334 1.0× 172 3.2k
Masami Kosuge Japan 34 2.5k 0.7× 491 0.6× 1.2k 2.1× 221 0.4× 404 1.2× 200 3.6k
Byung‐Su Yoo South Korea 32 2.5k 0.7× 334 0.4× 962 1.6× 190 0.3× 757 2.3× 225 3.9k
Connie N. Hess United States 28 1.5k 0.4× 540 0.7× 1.6k 2.7× 426 0.8× 728 2.2× 90 3.2k
Steven L. Zelenkofske United States 17 2.9k 0.8× 661 0.9× 637 1.1× 103 0.2× 442 1.4× 29 4.1k

Countries citing papers authored by C. B. Granger

Since Specialization
Citations

This map shows the geographic impact of C. B. Granger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. B. Granger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. B. Granger more than expected).

Fields of papers citing papers by C. B. Granger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. B. Granger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. B. Granger. The network helps show where C. B. Granger may publish in the future.

Co-authorship network of co-authors of C. B. Granger

This figure shows the co-authorship network connecting the top 25 collaborators of C. B. Granger. A scholar is included among the top collaborators of C. B. Granger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. B. Granger. C. B. Granger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Held, Claes, Elaine M. Hylek, John H. Alexander, et al.. (2014). Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. European Heart Journal. 36(20). 1264–1272. 124 indexed citations
2.
Halvorsen, Sigrun, Dan Atar, H. Yang, et al.. (2014). Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal. 35(28). 1864–1872. 262 indexed citations
3.
Stewart, Ralph, Claes Held, Ola Vedin, et al.. (2013). Physical activity in patients with stable coronary heart disease: an international perspective. European Heart Journal. 34(42). 3286–3293. 70 indexed citations
4.
Fosbøl, Emil Loldrup, C. B. Granger, Barbara L. Lytle, et al.. (2011). Abstract 16674: Using Novel Emergency Medical Services Data-Linkage to Evaluate the Timing and Quality of Pre-Hospital ST-Elevation Myocardial Infarction Care. Circulation. 124(suppl_21). 1 indexed citations
5.
Oldgren, Jonas, Andrzej Budaj, C. B. Granger, et al.. (2011). Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal. 32(22). 2781–2789. 369 indexed citations
6.
Crosslin, David R., Svati H. Shah, Sarah C. Nelson, et al.. (2009). Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. Human Genetics. 125(2). 217–229. 46 indexed citations
7.
Fox, Keith A.A., Kathryn Carruthers, Philippe Gabríel Steg, et al.. (2009). Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. European Heart Journal. 31(6). 667–675. 47 indexed citations
8.
Budaj, Andrzej, John W. Eikelboom, R. Afzal, et al.. (2008). Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. European Heart Journal. 30(6). 655–661. 127 indexed citations
9.
Hauser, Elizabeth R., Svati H. Shah, David Seo, et al.. (2008). Polymorphisms of the Tumor Suppressor GeneLSAMPare Associated with Left Main Coronary Artery Disease. Annals of Human Genetics. 72(4). 443–453. 23 indexed citations
10.
MacDonald, Michael R., Mark C. Petrie, Fumi Varyani, et al.. (2008). Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal. 29(11). 1377–1385. 503 indexed citations breakdown →
11.
Oldgren, Jonas, Lars Wallentin, R. Afzal, et al.. (2007). Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. European Heart Journal. 29(3). 315–323. 30 indexed citations
12.
O’Meara, Eileen, Eldrin F. Lewis, C. B. Granger, et al.. (2005). Patient Perception of the Effect of Treatment with Candesartan in Heart Failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure. 7(4). 650–656. 21 indexed citations
13.
Solomon, Scott D., Bertil Olofsson, Peter Finn, et al.. (2004). 1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study. Journal of the American College of Cardiology. 43(5). A180–A180. 2 indexed citations
14.
Yusuf, Salim, Jan Östergren, Hertzel C. Gerstein, et al.. (2004). 810-1 Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure. Journal of the American College of Cardiology. 43(5). A473–A473. 5 indexed citations
15.
16.
Simes, John, Harvey D. White, Ian C. Marschner, et al.. (2002). International differences in patients, care, and outcomes associated with acute myocardial infarction: the hero-2 trial. Journal of the American College of Cardiology. 39. 280–280. 4 indexed citations
17.
Harrington, RA, Carmelo Graffagnino, Mark J. Alberts, et al.. (1998). Comparison of stroke rates in patients with acute coronary syndromes and patients with acute myocardial infarction. Journal of the American College of Cardiology. 31. 406–406.
18.
Wall, A. J., et al.. (1998). Failure to achieve optimal anticoagulation with commonly used heparin regimens; a review of GUSTO II. Journal of the American College of Cardiology. 31. 79–79. 6 indexed citations
19.
Granger, C. B., Paul W. Armstrong, John Simes, et al.. (1998). Hirudin reduces death and myocardial (RE)infarction at 6-months: follow-up results of the GUSTO IIb trial. Journal of the American College of Cardiology. 31. 79–79. 2 indexed citations
20.
Pilote, Louise, C. B. Granger, Paul W. Armstrong, Daniel B. Mark, & Mark A. Hlatky. (1995). Differences in the Treatment of Myocardial Infarction Between the United States and Canada. Medical Care. 33(6). 598–610. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Serafina Valente Breakdown of academic impact, for papers by Anselm K. Gitt Breakdown of academic impact, for papers by Erik Lerkevang Grove Breakdown of academic impact, for papers by Jayashri Aragam Breakdown of academic impact, for papers by Mikael Dellborg Breakdown of academic impact, for papers by Young‐Hoon Jeong Breakdown of academic impact, for papers by Masami Kosuge Breakdown of academic impact, for papers by Byung‐Su Yoo Breakdown of academic impact, for papers by Connie N. Hess Breakdown of academic impact, for papers by Steven L. Zelenkofske
Rankless by CCL
2026